Your browser doesn't support javascript.
loading
Durability of immune responses to the booster mRNA vaccination against COVID-19
Prabhu S Arunachalam; Lilin Lai; Hady Samaha; Yupeng Feng; Mengyun Hu; Harold Sai-yin Hui; Bushra Wali; Madison Ellis; Christopher Huerta; Kareem Bechnack; Sarah Bechnack; Matthew Lee; Matthew Litvack; Cecilia Losada; Alba Grifoni; Alessandro Sette; Veronika I Zarnitsyna; Nadine Rouphael; Mehul S Suthar; Bali Pulendran.
Affiliation
  • Prabhu S Arunachalam; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA, USA
  • Lilin Lai; Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Atlanta, GA, USA.
  • Hady Samaha; Hope Clinic of the Emory Vaccine Center, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Decatur, GA 30030, USA
  • Yupeng Feng; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
  • Mengyun Hu; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
  • Harold Sai-yin Hui; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
  • Bushra Wali; Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Atlanta, GA, USA
  • Madison Ellis; Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Atlanta, GA, USA.
  • Christopher Huerta; Hope Clinic of the Emory Vaccine Center, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Decatur, GA 30030, USA.
  • Kareem Bechnack; Hope Clinic of the Emory Vaccine Center, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Decatur, GA 30030, USA.
  • Sarah Bechnack; Hope Clinic of the Emory Vaccine Center, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Decatur, GA 30030, USA.
  • Matthew Lee; Hope Clinic of the Emory Vaccine Center, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Decatur, GA 30030, USA.
  • Matthew Litvack; Hope Clinic of the Emory Vaccine Center, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Decatur, GA 30030, USA.
  • Cecilia Losada; Hope Clinic of the Emory Vaccine Center, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Decatur, GA 30030, USA.
  • Alba Grifoni; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Alessandro Sette; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
  • Veronika I Zarnitsyna; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30329, USA.
  • Nadine Rouphael; Hope Clinic of the Emory Vaccine Center, Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Decatur, GA 30030, USA.
  • Mehul S Suthar; Department of Pediatrics, Emory Vaccine Center, Emory National Primate Research Center, Atlanta, GA, USA.
  • Bali Pulendran; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Preprint de En | PREPRINT-MEDRXIV | ID: ppmedrxiv-22282921
ABSTRACT
Waning immunity to vaccination represents a major challenge in vaccinology. Whether booster vaccination improves the durability of immune responses is unknown. Here we show, using a cohort of 55 adult vaccinees who received the BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine against SARS-CoV-2, that a booster (i.e., 3rd immunization) dose at 6 - 10 months increased the half-life of serum neutralizing antibody (nAb) titers to 76 days from 56 - 66 days estimated after the primary two-dose vaccination series. A second booster dose (i.e., 4th immunization) more than a year after the primary vaccination increased the half-life further to 88 days. However, despite this modestly improved durability in nAb responses against the Wuhan strain, there was a loss in neutralization capacity against Omicron subvariants, especially the recently emerged variants, BA.2.75.2 and BQ.1.1 (35 and 50-fold drop in titers respectively, relative to the ancestral (WA.1) strain. While only 55 - 65% of participants demonstrated a detectable nAb titer against the newer variants after the booster (3rd dose), the response declined to below the detection limit in almost all individuals by 6 months. Notably, even against BA.1 and BA.5, the titers declined rapidly in a third of the vaccinees and were below the detection limit at 6 months. In contrast, booster vaccination induced antigen-specific memory B and T cells that persisted for at least 6 months. Collectively, our data show that the durability of immune responses improves following subsequent booster immunizations; however, the emergence of immune evasive variants reduces the effectiveness of booster doses in preventing infection.
Licence
cc_no
Texte intégral: 1 Collection: 09-preprints Base de données: PREPRINT-MEDRXIV Type d'étude: Cohort_studies / Observational_studies / Prognostic_studies Langue: En Année: 2022 Type de document: Preprint
Texte intégral: 1 Collection: 09-preprints Base de données: PREPRINT-MEDRXIV Type d'étude: Cohort_studies / Observational_studies / Prognostic_studies Langue: En Année: 2022 Type de document: Preprint